Martin J. Cline

Martin J. Cline was an American physician and researcher known for early work in hematology and experimental gene therapy. He held appointments at prominent institutions including University of California, Los Angeles, Cedars-Sinai Medical Center, and had interactions with federal agencies such as the National Institutes of Health and the Food and Drug Administration. Cline's work intersected with figures and institutions across medicine and policy, prompting debate involving National Academy of Sciences, bioethicists, and congressional committees.

Early life and education

Cline was born in Cleveland, Ohio and attended Dartmouth College before earning his medical degree at Yale School of Medicine, where contemporaries included physicians associated with Massachusetts General Hospital and researchers linked to Harvard Medical School. His postgraduate training involved connections to clinical centers such as Beth Israel Hospital and research programs affiliated with the National Cancer Institute and the National Institutes of Health. Early mentorship and collaboration drew from networks including faculty from Stanford University School of Medicine, Johns Hopkins Hospital, and researchers active at Cold Spring Harbor Laboratory and Roswell Park Comprehensive Cancer Center.

Scientific career and research

Cline's scientific career encompassed hematology, culture techniques, and experimental approaches to modify human cells, building on advances from laboratories at Harvard Medical School, University of Pennsylvania, and Columbia University. He published on ex vivo manipulation of hematopoietic cells and leveraged methods informed by work at Salk Institute and Mayo Clinic. Collaborations and professional exchange linked him to investigators at UCLA Medical Center, Cedars-Sinai Medical Center, and research programs funded by the National Institutes of Health and the National Science Foundation. His laboratory techniques referenced evolving protocols from groups at Cold Spring Harbor Laboratory, Pasteur Institute, and teams working on human cell culture at Scripps Research and Fred Hutchinson Cancer Research Center.

Controversial human gene therapy experiments

In the 1980s Cline conducted ex vivo gene transfer procedures that became focal points in debates involving the Food and Drug Administration, the National Institutes of Health, and oversight bodies such as the National Academy of Sciences and the Institute of Medicine. His interventions prompted investigations by institutional review boards and inquiries resonating with congressional oversight committees including those in the United States Congress and hearings reminiscent of earlier biomedical controversies like hearings involving Tuskegee Syphilis Study exposures and debates following the HeLa cell controversies. Ethical critique and media coverage invoked commentators from The New York Times, Science (journal), and Nature (journal), alongside bioethicists associated with Kennedy Institute of Ethics, Hastings Center, and the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Legal and regulatory responses engaged officials from the Department of Health and Human Services, counseling from the National Institutes of Health Recombinant DNA Advisory Committee, and statements from leaders at Cedars-Sinai Medical Center and UCLA Health.

Later career and legal/ethical repercussions

Following public and regulatory scrutiny Cline faced institutional sanctions and professional consequences involving administrations at UCLA, Cedars-Sinai Medical Center, and attention from agencies such as the Food and Drug Administration and the National Institutes of Health. The episode influenced policy debates within bodies like the National Academy of Sciences, the Institute of Medicine, and advisory groups at the World Health Organization. Legal and ethical discourse included participation from scholars at Georgetown University, Columbia University, and Harvard University, and commentary published in venues associated with JAMA, The Lancet, and Science (journal). The controversy contributed to evolving oversight frameworks later discussed in relation to cases at institutions such as Stanford University, University of Pennsylvania, and regulatory reforms addressed by the United States Congress and executive branch agencies.

Publications and scientific legacy

Cline authored articles and participated in conferences alongside researchers from Cold Spring Harbor Laboratory, Salk Institute, Fred Hutchinson Cancer Research Center, and universities including Yale University, Harvard University, and University of California, San Francisco. His work is cited in historical and ethical analyses produced by scholars from Princeton University, Oxford University, and research centers such as Wellcome Trust-affiliated institutes. The legacy of his experiments is discussed in texts and reviews appearing in journals like Nature (journal), Science (journal), JAMA, and The New England Journal of Medicine, and in policy reports from the National Academies Press and the World Health Organization. Debates sparked by his career influenced subsequent gene therapy milestones at institutions including University of Pennsylvania (chimeric antigen receptor research), St. Jude Children's Research Hospital (gene therapy trials), and biotechnology efforts connected to Genentech, Amgen, and academic spinouts from Massachusetts Institute of Technology and Stanford University.

Category:American physicians Category:20th-century physicians